Cargando…
Is the Efficacy of Adding Ramucirumab to Docetaxel Related to a History of Immune Checkpoint Inhibitors in the Real-World Clinical Practice?
SIMPLE SUMMARY: Previous studies have shown that the use of chemotherapy in combination with immune checkpoint inhibitors as a first-line treatment in patients with non-small cell lung cancer improved overall survival and progression-free survival. However, the efficacy of cytotoxic agents as a seco...
Autores principales: | Nishimura, Tadashi, Fujimoto, Hajime, Okano, Tomohito, Naito, Masahiro, Tsuji, Chikashi, Iwanaka, Soichi, Sakakura, Yasumasa, Yasuma, Taro, D’Alessandro-Gabazza, Corina N., Oomoto, Yasuhiro, Gabazza, Esteban C., Kobayashi, Tetsu, Ibata, Hidenori |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221111/ https://www.ncbi.nlm.nih.gov/pubmed/35740634 http://dx.doi.org/10.3390/cancers14122970 |
Ejemplares similares
-
Complete withdrawal of glucocorticoids after dupilumab therapy in allergic bronchopulmonary aspergillosis: A case report
por: Nishimura, Tadashi, et al.
Publicado: (2021) -
Second‐line therapy with first‐ or second‐generation tyrosine kinase inhibitors in EGFR‐mutated non‐small cell lung cancer patients with T790M‐negative or unidentified mutation
por: Nishimura, Tadashi, et al.
Publicado: (2021) -
Next‐generation sequencing clarified why first‐line treatment with osimertinib was ineffective in an autopsied case of EGFR‐mutated lung squamous cell carcinoma
por: Nishimura, Tadashi, et al.
Publicado: (2023) -
Response of Lung Microbiota to Changes of Pulmonary Innate Immunity under Healthy Conditions
por: Yasuma, Taro, et al.
Publicado: (2021) -
The Need for a CYFRA 21-1 Cutoff Value to Predict Clinical Progression of IPF in Clinical Practice
por: Fujimoto, Hajime, et al.
Publicado: (2022)